Board of Directors

Dr Peter Fellner

Chairman

Appointed to the Board

14 November 2005. Chairman since May 2009

Current Roles

Dr Fellner is currently Chairman of Vernalis plc, Ablynx nv and Mereo Biopharma Group plc

Committees

Peter is Chairman of the Nomination Committee.

Skills & Experience

Peter previously served as Chairman of Celltech Group plc from 2003 to July 2004, having been CEO from 1990 onwards. Before joining Celltech he was CEO of Roche UK from 1986 to 1990.

More recently he has been involved in a wide range of companies. These have included serving as Chairman of Optos plc from 2010 to 2015, until its acquisition by Nikon Corporation. He was also Chairman of Acambis plc from 2006, until its acquisition by Sanofi in 2008, and Chairman of Premier Research Group plc from 2007 to 2008, when it was acquired by a private-equity backed group. In addition, he was Vice Chairman of Astex Pharmaceuticals, Inc. from 2011 to 2013 when it was acquired by Otsuka. He was a Director of the global biopharmaceutical company UCB SA from 2005 to 2014, and also served as a Director of QinetiQ Group plc (2004-2009) and Evotec AG (2005-2011). He was a member of the Novo A/S Advisory Group from 2010 to 2016. He was a member of the Medical Research Council from 2000 to 2007.

In summary, Peter has many years' experience in the pharmaceutical and biotechnology industry including senior R&D, executive and non-executive appointments.

Jonathan Glenn

Chief Executive Officer

Appointed to the Board

11 September 2006. CEO since December 2007

Current Roles

Chief Executive Officer

Committees

Mr Glenn is a member of the Nomination Committee and the Corporate Responsibility Committee.

Skills & Experience

Jonathan was Group Finance Director of Consort Medical plc from September 2006 to December 2007 until he took up the position of Chief Executive Officer in December 2007. Prior to joining Consort Medical plc, Jonathan was global Head of Finance at Celltech Group plc and later Chief Financial Officer of Akubio Ltd, a Cambridge-based developer of instrumentation for the life sciences industry. Jonathan joined Tissue Regenix Group plc as a non-executive director in January 2016 and is an investor director of Atlas Genetics Limited.

Jonathan is a member of the Institute of Chartered Accountants in England and Wales.

Paul Hayes

Chief Financial Officer

Appointed to the Board

1 May 2017

Current Role

Chief Financial Officer

Committees

Paul attends the Audit Committee at the invitation of the Chairman.

Skills & Experience

Paul was Group Finance Director of Vitec Group plc, between June 2011 and April 2017. Previously he was Group Financial Controller at Signet Jewelers Limited (formerly Signet Group plc) between 2007 and 2011. Prior to that he held a senior role at RHM plc from 2004 to 2007 through its flotation in 2005 and subsequent sale to Premier Foods plc. Paul was with Smiths Group plc for over ten years from 1993, including a number of divisional and operating company finance director roles.

He is a Chartered Accountant having qualified with Ernst & Young LLP, and has a first class Masters degree in Mechanical Engineering, Manufacture & Management.

Ian Nicholson

Non-executive Director

Appointed to the Board

13 June 2012

Current Roles

Mr Nicholson is also Chief Executive Officer of F2G Ltd, a UK-based antifungal drug discovery and development company, Chairman of Bioventix plc, a diagnostics company, non-executive director of Clinigen Group plc, a specialty pharmaceuticals and services business, and also an Operating Partner at Advent Life Sciences LLP.

Committees

Ian is Chair of the Corporate Responsibility Committee and a member of the Nomination Committee.

Skills & Experience

From 2004 to 2012, Ian was Chief Executive of Chroma Therapeutics Limited, and from 2000 to 2004 Senior Vice President, Business Development at Celltech Group plc.

In addition to his Chief Executive experience, Ian has extensive experience in business development, licensing and mergers and acquisitions in the UK, Europe and the US.

Dr William Jenkins

Non-executive Director

Appointed to the Board

6 May 2009. Senior Independent Director since 1 September 2011

Current Roles

Dr Jenkins is a non-executive director of Ablynx nv and Allecra Therapeutics GmbH. He is also a member of the Scientific Advisory board of BB Biotech Ventures and a member of the Strategic Advisory Board of Chiesi Farmaceutici SpA. He is principal of William Jenkins Pharma Consulting.

Committees

William is Chair of the Remuneration Committee and a member of the Nomination Committee.

Skills & Experience

Formerly head of Worldwide Clinical Development and Regulatory Affairs for Novartis Pharma AG and held similar positions with Ciba Geigy AG and Glaxo.

Dr Andrew Hosty

Non-Executive Director

Appointed to the Board

14 July 2014

Current Roles

Dr Hosty is Chief Executive of the Sir Henry Royce Institute for Advanced Materials and non-executive Chairman of mOm Incubators Ltd.

Committees

Andrew is a member of the Audit, Remuneration and Nomination Committees.

Skills & Experience

From February 2013 until January 2016, Andrew was Chief Operating Officer at Morgan Advanced Materials plc. Before this, he held a number of senior positions within Morgan Advanced Materials plc, including as Chief Executive Officer of Morgan Ceramics and joined the Morgan Advanced Materials plc Board in July 2010. Previously he was a non-executive director of Fiberweb plc from 2012 to 2013 and President of the British Ceramics confederation from 2003 to 2005. He is a Fellow of the Royal Academy of Engineering.

Charlotta Ginman

Non-Executive Director

Appointed to the Board

11 February 2015

Current Roles

Ms Ginman is a non-executive director and Chairman of the Audit Committee for Motif Bio plc, Pacific Assets Trust and Polar Capital Technology Trust PLC. Furthermore, she is a non-executive director for Unicorn AIM VCT plc.

Committees

Charlotta is a member of the Audit and Nomination Committees.

Skills & Experience

Charlotta qualified as a Chartered Accountant at Ernst & Young before spending a career in investment banking and commercial organisations, principally in technology-related businesses. Charlotta began her career at Ernst & Young LLP, joining in 1989, and then held a series of senior roles in investment banking with UBS, Deutsche Bank and JP Morgan. Charlotta has also held senior roles within Nokia Corp. and Vertu Corp. Ltd.

Until 16 December 2015, Charlotta was a non-executive director at Kromek Group plc and was previously a non-executive director of Wolfson Microelectronics plc.

Steve Crummett

Non-executive Director

Appointed to the Board

13 June 2012

Current Roles

Finance Director of Morgan Sindall Group plc

Committees

Mr Crummett is Chair of the Audit Committee and a member of the Remuneration Committee and the Nomination Committee.

Skills & Experience

Steve is a Chartered Accountant and was Group Finance Director of Filtrona plc (now Essentra plc) from 2008 to 2012 having previously held senior finance roles with a number of listed companies.